Gag-Pol Processing during HIV-1 Virion Maturation: A Systems Biology Approach

PLoS Computational Biology

Volumn 9, Issue 6, 2013, Pages

  Könnyu, Balázs ^a   Sadiq, S Kashif ^b   Turányi, Tamás ^a   Hírmondó, Rita ^a,c   Müller, Barbara ^d   Kräusslich, Hans Georg ^d   Coveney, Peter V ^e   Müller, Viktor ^a,f  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c INSTITUTE OF ENZYMOLOGY   (Hungary)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DOSAGE; REACTION INTERMEDIATES; REACTION KINETICS; UNCERTAINTY ANALYSIS;

'CURRENT; ANTIRETROVIRALS; CLEAVAGE SITES; INTEGRAL PART; OPTIMAL TREATMENT; POLYPROTEINS; PROTEOLYTIC PROCESSING; SYSTEM-LEVEL APPROACH; SYSTEMS BIOLOGY; VIRAL PROTEASE;

ENZYMES;

DARUNAVIR; GAG PROTEIN; POL PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DOSE RESPONSE; DRUG BINDING SITE; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEOLYTIC PROCESSING; SYSTEMS BIOLOGY; VIRION; VIROGENESIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84879534949     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003103     Document Type: Article

References (87)

1. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, et al. (1988) Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 85: 4686-4690.
2. Anderson J, Schiffer C, Lee SK, Swanstrom R, (2009) Viral protease inhibitors. Handb Exp Pharmacol 189: 85-110.
3. Wensing AM, van Maarseveen NM, Nijhuis M, (2010) Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res 85: 59-74.
4. Adamson CS, Salzwedel K, Freed EO, (2009) Virus maturation as a new HIV-1 therapeutic target. Expert Opin Ther Targets 13: 895-908.
5. Waheed AA, Freed EO, (2012) HIV type 1 Gag as a target for antiviral therapy. AIDS Res Hum Retroviruses 28: 54-75.
6. Debouck C, Gorniak JG, Strickler JE, Meek TD, Metcalf BW, et al. (1987) Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci USA 84: 8903-8906.
7. Strickler JE, Gorniak J, Dayton B, Meek T, Moore M, et al. (1989) Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli. Proteins 6: 139-154.
8. Louis JM, Nashed NT, Parris KD, Kimmel AR, Jerina DM, (1994) Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. Proc Natl Acad Sci USA 91: 7970-7974.
9. Louis JM, Wondrak EM, Kimmel AR, Wingfield PT, Nashed NT, (1999) Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism. J Biol Chem 274: 23437-23442.
10. Beck ZQ, Morris GM, Elder JH, (2002) Defining HIV-1 protease substrate selectivity. Curr Drug Targets Infect Disord 2: 37-50.
11. Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R, (2002) Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol 76: 10226-10233.
12. Barik D, Baumann WT, Paul MR, Novak B, Tyson JJ, (2010) A model of yeast cell-cycle regulation based on multisite phosphorylation. Mol Syst Biol 6: 405.
13. Tözsér J, Blaha I, Copeland TD, Wondrak EM, Oroszlan S, (1991) Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett 281: 77-80.
14. Darke PL, Jordan SP, Hall DL, Zugay JA, Shafer JA, et al. (1994) Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates. Biochemistry 33: 98-105.
15. Mildner AM, Rothrock DJ, Leone JW, Bannow CA, Lull JM, et al. (1994) The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry 33: 9405-9413.
16. Fehér A, Weber IT, Bagossi P, Boross P, Mahalingam B, et al. (2002) Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem 269: 4114-4120.
17. Tözsér J, Shulenin S, Kadas J, Boross P, Bagossi P, et al. (2003) Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis. Virology 310: 16-23.
18. Ludwig C, Leiherer A, Wagner R, (2008) Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation. J Virol 82: 4573-4584.
19. Noel AF, Bilsel O, Kundu A, Wu Y, Zitzewitz JA, et al. (2009) The folding free-energy surface of HIV-1 protease: insights into the thermodynamic basis for resistance to inhibitors. J Mol Biol 387: 1002-1016.
20. Breuer S, Sepulveda H, Chen Y, Trotter J, Torbett BE, (2011) A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease. Biochemistry 50: 4371-4381.
21. Briggs JA, Riches JD, Glass B, Bartonova V, Zanetti G, et al. (2009) Structure and assembly of immature HIV. Proc Natl Acad Sci USA 106: 11090-11095.
22. Carlson LA, Briggs JA, Glass B, Riches JD, Simon MN, et al. (2008) Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. Cell Host Microbe 4: 592-599.
23. Ivanchenko S, Godinez WJ, Lampe M, Krausslich HG, Eils R, et al. (2009) Dynamics of HIV-1 assembly and release. PLoS Pathog 5: e1000652.
24. Jouvenet N, Simon SM, Bieniasz PD, (2011) Visualizing HIV-1 assembly. J Mol Biol 410: 501-511.
25. Wright ER, Schooler JB, Ding HJ, Kieffer C, Fillmore C, et al. (2007) Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. EMBO J 26: 2218-2226.
26. de Marco A, Muller B, Glass B, Riches JD, Krausslich HG, et al. (2010) Structural analysis of HIV-1 maturation using cryo-electron tomography. PLoS Pathog 6: e1001215.
27. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14: 762-766.
28. Pettit SC, Clemente JC, Jeung JA, Dunn BM, Kaplan AH, (2005) Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J Virol 79: 10601-10607.
29. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK, (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458-466.
30. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
31. Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, et al. (2004) The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 11: 672-675.
32. Accola MA, Hoglund S, Gottlinger HG, (1998) A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly. J Virol 72: 2072-2078.
33. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, et al. (1998) Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol 72: 2846-2854.
34. Checkley MA, Luttge BG, Soheilian F, Nagashima K, Freed EO, (2010) The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. Virology 400: 137-144.
35. Müller B, Anders M, Akiyama H, Welsch S, Glass B, et al. (2009) HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem 284: 29692-29703.
36. Adamson CS, Freed EO, (2007) Human immunodeficiency virus type 1 assembly, release, and maturation. Adv Pharmacol 55: 347-387.
37. Jouvenet N, Bieniasz PD, Simon SM, (2008) Imaging the biogenesis of individual HIV-1 virions in live cells. Nature 454: 236-240.
38. Pettit SC, Lindquist JN, Kaplan AH, Swanstrom R, (2005) Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology 2: 66.
39. Sadiq SK, Könnyü B, Müller V, Coveney PV, (2011) Reaction kinetics of catalyzed competitive heteropolymer cleavage. J Phys Chem B 115: 11017-11027.
40. Briggs JA, Wilk T, Welker R, Krausslich HG, Fuller SD, (2003) Structural organization of authentic, mature HIV-1 virions and cores. EMBO J 22: 1707-1715.
41. Benjamin J, Ganser-Pornillos BK, Tivol WF, Sundquist WI, Jensen GJ, (2005) Three-dimensional structure of HIV-1 virus-like particles by electron cryotomography. J Mol Biol 346: 577-588.
42. Lovrics A, Zsély IG, Csikász-Nagy A, Zádor J, Turányi T, et al. (2008) Analysis of a budding yeast cell cycle model using the shapes of local sensitivity functions. International Journal of Chemical Kinetics 40: 710-720.
43. Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, et al. (2007) Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 81: 13845-13851.
44. Koh Y, Matsumi S, Das D, Amano M, Davis DA, et al. (2007) Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 282: 28709-28720.
45. Shen L, Rabi SA, Sedaghat AR, Shan L, Lai J, et al. (2011) A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci Transl Med 3: 91ra63.
46. Perelson AS, Deeks SG, (2011) Drug effectiveness explained: the mathematics of antiviral agents for HIV. Sci Transl Med 3: 91ps30.
47. Doyon L, Payant C, Brakier-Gingras L, Lamarre D, (1998) Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 72: 6146-6150.
48. Back D, Sekar V, Hoetelmans RM, (2008) Darunavir: pharmacokinetics and drug interactions. Antivir Ther 13: 1-13.
49. Kwan WS, Janneh O, Hartkoorn R, Chandler B, Khoo S, et al. (2009) Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol 68: 375-380.
50. Jackson A, Watson V, Back D, Khoo S, Liptrott N, et al. (2011) Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr 58: 450-457.
51. Sedaghat AR, Wilke CO, (2011) Kinetics of the viral cycle influence pharmacodynamics of antiretroviral therapy. Biol Direct 6: 42.
52. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, et al. (2007) A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 4: e36.
53. van Maarseveen NM, Andersson D, Lepsik M, Fun A, Schipper PJ, et al. (2012) Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. Retrovirology 9: 29.
54. Kräusslich HG, (1991) Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc Natl Acad Sci USA 88: 3213-3217.
55. Wondrak EM, Nashed NT, Haber MT, Jerina DM, Louis JM, (1996) A transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of maturation. J Biol Chem 271: 4477-4481.
56. Bharat TA, Davey NE, Ulbrich P, Riches JD, de Marco A, et al. (2012) Structure of the immature retroviral capsid at 8 A resolution by cryo-electron microscopy. Nature 487: 385-389.
57. Briggs JA, Krausslich HG, (2011) The molecular architecture of HIV. J Mol Biol 410: 491-500.
58. Lee SK, Potempa M, Swanstrom R, (2012) The choreography of HIV-1 proteolytic processing and virion assembly. J Biol Chem 287: 40867-40874.
59. Gillespie DT, (2007) Stochastic simulation of chemical kinetics. Annu Rev Phys Chem 58: 35-55.
60. Douglas CC, Thomas D, Lanman J, Prevelige PE Jr, (2004) Investigation of N-terminal domain charged residues on the assembly and stability of HIV-1 CA. Biochemistry 43: 10435-10441.
61. Mirambeau G, Lyonnais S, Coulaud D, Hameau L, Lafosse S, et al. (2007) HIV-1 protease and reverse transcriptase control the architecture of their nucleocapsid partner. PLoS One 2: e669.
62. di Marzo Veronese F, Copeland TD, DeVico AL, Rahman R, Oroszlan S, et al. (1986) Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 231: 1289-1291.
63. Welker R, Kottler H, Kalbitzer HR, Krausslich HG, (1996) Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 219: 228-236.
64. Sluis-Cremer N, Arion D, Abram ME, Parniak MA, (2004) Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. Int J Biochem Cell Biol 36: 1836-1847.
65. Dale BM, McNerney GP, Thompson DL, Hubner W, de Los Reyes K, et al. (2011) Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusion. Cell Host Microbe 10: 551-562.
66. Fu W, Rein A, (1993) Maturation of dimeric viral RNA of Moloney murine leukemia virus. J Virol 67: 5443-5449.
67. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, et al. (1999) Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354: 1782-1785.
68. Müller V, Maree AF, De Boer RJ, (2001) Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood. J Virol 75: 2597-2603.
69. De Boer RJ, Ribeiro RM, Perelson AS, (2010) Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues. PLoS Comput Biol 6: e1000906.
70. Sattentau QJ, (2010) Cell-to-Cell Spread of Retroviruses. Viruses 2: 1306-1321.
71. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ, (2004) HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 199: 283-293.
72. Rasnick D, (1997) Kinetics analysis of consecutive HIV proteolytic cleavages of the Gag-Pol polyprotein. J Biol Chem 272: 6348-6353.
73. Snyder S, D'Argenio DZ, Weislow O, Bilello JA, Drusano GL, (2000) The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob Agents Chemother 44: 1051-1058.
74. Lin YC, Brik A, de Parseval A, Tam K, Torbett BE, et al. (2006) Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system. J Virol 80: 7832-7843.
75. Vana ML, Chen A, Boross P, Weber I, Colman D, et al. (2005) Mutations affecting cleavage at the p10-capsid protease cleavage site block Rous sarcoma virus replication. Retrovirology 2: 58.
76. Menendez-Arias L, Weber IT, Soss J, Harrison RW, Gotte D, et al. (1994) Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease. J Biol Chem 269: 16795-16801.
77. Louis JM, Clore GM, Gronenborn AM, (1999) Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat Struct Biol 6: 868-875.
78. Pettit SC, Everitt LE, Choudhury S, Dunn BM, Kaplan AH, (2004) Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J Virol 78: 8477-8485.
79. Sadiq SK, Noe F, De Fabritiis G, (2012) Kinetic characterization of the critical step in HIV-1 protease maturation. Proc Natl Acad Sci USA 109: 20449-20454.
80. Chatterjee A, Mridula P, Mishra RK, Mittal R, Hosur RV, (2005) Folding regulates autoprocessing of HIV-1 protease precursor. J Biol Chem 280: 11369-11378.
81. Wondrak EM, Louis JM, (1996) Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. Biochemistry 35: 12957-12962.
82. Press WH, Teukolsky SA, Vetterling WT, Flannery BT (1992) Numerical Recipes in C: the art of scientific computing. New York: Cambridge University Press.
83. Caracotsios M, Stewart WE, (1985) Sensitivity analysis of initial value problems with mixed odes and algebraic equations. Computers & Chemical Engineering 9: 359-365.
84. Crank J (1975) The Mathematics of Diffusion. Oxford: Clarendon Press.
85. Wilke CR, Chang P, (1955) Correlation of diffusion coefficients in dilute solutions. AICHE J 1: 264-270.
86. R Core Team (2012) R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing.
87. Divita G, Restle T, Goody RS, (1993) Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence. FEBS Lett 324: 153-158.